CARB-X News

• 02.26.2025  |  CARB-X launches 2025 Funding Round targeting global infectious disease threats

  CARB-X announces 2025 Funding Round seeking therapeutics for infections caused by Gram-negative pathogens and diagnostics for Salmonella Typhi

  Full Story

• 02.25.2025  |  CARB-X funds Immunethep to develop vaccine to prevent E. coli infections

  CARB-X will award $2 million to Immunethep to develop a conjugated peptide-based vaccine to prevent infections from all invasive serotypes of Escherichia coli.

  Full Story

• 02.11.2025  |  CARB-X funds Pearl to assess detection of bacterial pneumonia via urine sample

  CARB-X will award biotechnology Pearl Diagnostics US$1.M to develop a low-cost, low turnaround time urine assay for the detection of pneumonia caused by Pseudomonas aeruginosa.

  Full Story

• 02.06.2025  |  CARB-X funds AstraDx to develop rapid diagnostic to detect neonatal sepsis

  CARB-X will award AstraDx US$3M to demonstrate feasibility ahead of development for a robust, low-cost instrument to detect neonatal sepsis. AstraDx’s technology aims to perform pathogen detection, pathogen identification, and phenotypic antimicrobial susceptibility testing (AST) directly from whole blood and produce results within 4 hours.

  Full Story

• 01.28.2025  |  CARB-X funds Rhode Island Hospital to assess feasibility of direct from blood detection of bacterial pneumonia

  CARB-X will award Rhode Island Hospital at Brown University Health US$1M to demonstrate proof-of-concept of a polymerase chain reaction (PCR) approach informed by RNA sequencing to detect bacterial pneumonia directly from whole blood.

  Full Story

• 01.23.2025  |  CARB-X funds Immunartes to develop Staphylococcus aureus preventative

  CARB-X will award Immunartes US$729k to develop a monoclonal antibody to prevent infections caused by Staphylococcus aureus.

  Full Story

• 01.16.2025  |  CARB-X funds Justus Liebig University Giessen to develop antibiotic targeting Gram-negative pathogens

  CARB-X will award a seed grant of US$610k to Justus Liebig University Giessen (JLU) to support the definition of a lead optimization path for the development of a direct-acting peptide therapeutic based on a natural-product scaffold targeting Gram-negative pathogens.

  Full Story

• 01.14.2025  |  CARB-X funds Melio to develop rapid diagnostic to detect neonatal sepsis

  CARB-X will award biotechnology company Melio US$3.5M to develop and execute a technical feasibility workplan for its culture-free platform designed to identify blood stream infections including neonatal sepsis. 

  Full Story

• 01.09.2025  |  CARB-X funds Peptilogics to develop a novel, broad-spectrum therapeutic to treat fracture-related infections

  CARB-X will award Peptilogics $3.3 million to develop and execute a workplan for its slow-release formulation of a novel, broad-spectrum therapeutic, zaloganan-CR, an engineered peptide intended for use in preventing infection after high-energy-traumatic bone injuries.

  Full Story

• 01.07.2025  |  CARB-X funds Clarametyx Biosciences to develop anti-biofilm vaccine

  CARB-X will award Clarametyx Biosciences US$2.6 million to develop a Lead Optimization workplan to support its novel broad-spectrum, anti-biofilm vaccine program.

  Full Story